Fujifilm starts new late-phase trial of Avigan in Japan for Covid-19 patients
Coronavirus chronicle
21 April, 2021, 09:10 am
Last modified: 21 April, 2021, 09:16 am
Tablets of Avigan are displayed during a photo opportunity at Fujifilm's headquarters in Tokyo. REUTERS/Issei Kato
Fujifilm Holdings Corp said on Wednesday it started a new phase III trial of its anti-influenza drug Avigan in Japan for Covid-19 patients.
The new trial in Japan is targeting patients with early-onset of Covid-19 who have risk factors for progression to severe symptoms, Fujifilm said in a release.
Domestic approval of the drug for Covid-19 was delayed after a health ministry panel said in December that trial data was inconclusive.
Comments
While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.